Physician profile
Albert Chiemprabha
NPI 1326003005
$11,314.78
in general payments reported to CMS, 2019-2025
34 companies · $2,437 in 2025
The $2,437 reported for 2025 was more than what 83% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $860 · 2020: $1,149 · 2021: $1,588 · 2022: $1,716 · 2023: $1,691 · 2024: $1,873 · 2025: $2,437.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,886 · Education: $115.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,886.45 |
| Education | $114.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,922.24 | 2019-2025 | Rinvoq, Skyrizi, Linzess |
| Janssen Biotech, INC. | $2,260.83 | 2019-2025 | Tremfya, Stelara, Remicade |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,672.47 | 2019-2024 | Xifaxan, Trulance, Plenvu |
| Takeda Pharmaceuticals U.S.A., INC. | $1,013.16 | 2019-2025 | Entyvio, Gattex, Eohilia |
| Phathom Pharmaceuticals, INC. | $540.50 | 2023-2025 | Voquezna |
| Celgene Corporation | $434.40 | 2021-2024 | Zeposia |
| Pfizer INC. | $381.09 | 2019-2025 | |
| Intercept Pharmaceuticals, INC. | $276.52 | 2020-2025 | Ocaliva |
| Ardelyx, INC. | $258.70 | 2022-2025 | Ibsrela |
| Qol Medical, LLC | $210.28 | 2024-2025 | Sucraid, Sucraid |
| Madrigal Pharmaceuticals | $186.05 | 2024-2025 | Resmetirom, Rezdiffra |
| Merck Sharp & Dohme LLC | $167.24 | 2023-2024 | Dificid |
| Ironwood Pharmaceuticals, INC | $152.94 | 2019-2024 | |
| Ferring Pharmaceuticals INC. | $103.03 | 2019-2024 | Rebyota |
| Celltrion USA INC. | $99.66 | 2024-2025 | Vegzelma, Zymfentra |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $95.29 | 2025 | Omvoh |
| Aimmune Therapeutics, INC. | $72.40 | 2025 | Zenpep, Vowst |
| Nestle Healthcare Nutrition INC. | $59.25 | 2021-2022 | |
| Braintree Laboratories, INC. | $53.64 | 2020-2023 | Sutab |
| Ucb, INC. | $44.57 | 2020-2023 | Cimzia |
| Novo Nordisk INC | $41.30 | 2025 | Wegovy, Saxenda |
| Ipsen Biopharmaceuticals, INC | $34.32 | 2025 | Iqirvo |
| Gilead Sciences, INC. | $32.92 | 2019-2025 | |
| Pharmacosmos Therapeutics INC. | $29.61 | 2020-2022 | |
| Shire North American Group INC | $28.12 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $25.80 | 2023 | Cyltezo |
| Evoke Pharma, INC. | $22.87 | 2023 | Gimoti |
| Alfasigma USA, INC. | $21.26 | 2020 | |
| Alnylam Pharmaceuticals INC. | $19.07 | 2023 | Givlaari |
| Endogastric Solutions, INC | $15.95 | 2022 | |
| Fresenius Kabi USA, LLC | $14.46 | 2023 | Idacio |
| Redhill Biopharma INC. | $13.61 | 2021 | |
| Allergan, INC. | $11.23 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$43,252.65 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Albert Chiemprabha listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.